Novo Nordisk A/S
NONOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $74,976 | $76,857 | $78,087 | $85,683 |
| % Growth | -2.4% | -1.6% | -8.9% | – |
| Cost of Goods Sold | $17,904 | $12,846 | $12,890 | $13,024 |
| Gross Profit | $57,072 | $64,011 | $65,197 | $72,659 |
| % Margin | 76.1% | 83.3% | 83.5% | 84.8% |
| R&D Expenses | $15,393 | $11,690 | $10,308 | $13,802 |
| G&A Expenses | $1,327 | $1,316 | $1,220 | $1,580 |
| SG&A Expenses | $17,323 | $18,849 | $16,112 | $20,281 |
| Sales & Mktg Exp. | $15,996 | $17,533 | $14,892 | $18,701 |
| Other Operating Expenses | $674 | $23 | -$14 | $1,839 |
| Operating Expenses | $33,390 | $30,562 | $26,406 | $35,922 |
| Operating Income | $23,682 | $33,449 | $38,791 | $36,737 |
| % Margin | 31.6% | 43.5% | 49.7% | 42.9% |
| Other Income/Exp. Net | $1,835 | $356 | -$1,758 | -$1,180 |
| Pre-Tax Income | $25,517 | $33,805 | $37,033 | $35,557 |
| Tax Expense | $5,511 | $7,302 | $7,999 | $7,327 |
| Net Income | $20,006 | $26,503 | $29,034 | $28,230 |
| % Margin | 26.7% | 34.5% | 37.2% | 32.9% |
| EPS | 4.5 | 5.96 | 6.54 | 6.34 |
| % Growth | -24.5% | -8.9% | 3.2% | – |
| EPS Diluted | 4.5 | 5.96 | 6.53 | 6.33 |
| Weighted Avg Shares Out | 4,446 | 4,447 | 4,440 | 4,454 |
| Weighted Avg Shares Out Dil | 4,447 | 4,447 | 4,446 | 4,461 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,314 | $5,314 | $3,425 | -$2,651 |
| Interest Expense | $5,007 | $4,958 | $5,183 | -$2,817 |
| Depreciation & Amortization | $3,237 | $4,833 | $3,830 | $5,198 |
| EBITDA | $33,761 | $43,596 | $46,046 | $40,142 |
| % Margin | 45% | 56.7% | 59% | 46.8% |